ARGENX SE (ARGX.BR) Stock Fundamental Analysis
Europe - Euronext Brussels - EBR:ARGX - NL0010832176 - Common Stock
783.6 EUR
+12.6 (+1.63%)
We assign a fundamental rating of 6 out of 10 to ARGX. ARGX was compared to 83 industry peers in the Biotechnology industry. ARGX has an excellent financial health rating, but there are some minor concerns on its profitability. ARGX is not overvalued while it is showing excellent growth. This is an interesting combination.
1. Profitability
1.1 Basic Checks
In the past year ARGX was profitable.
In the past year ARGX had a positive cash flow from operations.
In the past 5 years ARGX reported 4 times negative net income.
In the past 5 years ARGX always reported negative operating cash flow.
1.2 Ratios
ARGX has a Return On Assets of 17.84%. This is amongst the best in the industry. ARGX outperforms 90.36% of its industry peers.
The Return On Equity of ARGX (21.00%) is better than 87.95% of its industry peers.
ARGX has a better Return On Invested Capital (5.71%) than 78.31% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 17.84% | ||
| ROE | 21% | ||
| ROIC | 5.71% |
ROA(3y)-5.23%
ROA(5y)-11.34%
ROE(3y)-5.76%
ROE(5y)-13.95%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin of ARGX (41.97%) is better than 91.57% of its industry peers.
With a decent Operating Margin value of 15.30%, ARGX is doing good in the industry, outperforming 79.52% of the companies in the same industry.
ARGX has a better Gross Margin (89.40%) than 79.52% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 15.3% | ||
| PM (TTM) | 41.97% | ||
| GM | 89.4% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so ARGX is destroying value.
The number of shares outstanding for ARGX has been increased compared to 1 year ago.
Compared to 5 years ago, ARGX has more shares outstanding
ARGX has a worse debt/assets ratio than last year.
2.2 Solvency
ARGX has an Altman-Z score of 32.14. This indicates that ARGX is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 32.14, ARGX belongs to the top of the industry, outperforming 97.59% of the companies in the same industry.
ARGX has a debt to FCF ratio of 0.14. This is a very positive value and a sign of high solvency as it would only need 0.14 years to pay back of all of its debts.
ARGX's Debt to FCF ratio of 0.14 is amongst the best of the industry. ARGX outperforms 93.98% of its industry peers.
A Debt/Equity ratio of 0.01 indicates that ARGX is not too dependend on debt financing.
ARGX has a better Debt to Equity ratio (0.01) than 85.54% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | 0.14 | ||
| Altman-Z | 32.14 |
ROIC/WACC0.77
WACC7.43%
2.3 Liquidity
ARGX has a Current Ratio of 5.60. This indicates that ARGX is financially healthy and has no problem in meeting its short term obligations.
ARGX has a Current ratio of 5.60. This is amongst the best in the industry. ARGX outperforms 81.93% of its industry peers.
A Quick Ratio of 5.27 indicates that ARGX has no problem at all paying its short term obligations.
The Quick ratio of ARGX (5.27) is better than 84.34% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.6 | ||
| Quick Ratio | 5.27 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 1512.50% over the past year.
Looking at the last year, ARGX shows a very strong growth in Revenue. The Revenue has grown by 64.65%.
Measured over the past years, ARGX shows a very strong growth in Revenue. The Revenue has been growing by 94.61% on average per year.
EPS 1Y (TTM)1512.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%272.66%
Revenue 1Y (TTM)64.65%
Revenue growth 3Y63.92%
Revenue growth 5Y94.61%
Sales Q2Q%95.51%
3.2 Future
The Earnings Per Share is expected to grow by 107.34% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 34.98% on average over the next years. This is a very strong growth
EPS Next Y939.88%
EPS Next 2Y310.28%
EPS Next 3Y177.32%
EPS Next 5Y107.34%
Revenue Next Year94.97%
Revenue Next 2Y63.05%
Revenue Next 3Y48.34%
Revenue Next 5Y34.98%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 73.44, which means the current valuation is very expensive for ARGX.
73.49% of the companies in the same industry are more expensive than ARGX, based on the Price/Earnings ratio.
Compared to an average S&P500 Price/Earnings ratio of 26.34, ARGX is valued quite expensively.
ARGX is valuated quite expensively with a Price/Forward Earnings ratio of 31.33.
Based on the Price/Forward Earnings ratio, ARGX is valued a bit cheaper than the industry average as 78.31% of the companies are valued more expensively.
ARGX's Price/Forward Earnings ratio indicates a valuation a bit more expensive than the S&P500 average which is at 23.56.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 73.44 | ||
| Fwd PE | 31.33 |
4.2 Price Multiples
71.08% of the companies in the same industry are more expensive than ARGX, based on the Enterprise Value to EBITDA ratio.
Based on the Price/Free Cash Flow ratio, ARGX is valued a bit cheaper than 75.90% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 181.98 | ||
| EV/EBITDA | 101.37 |
4.3 Compensation for Growth
ARGX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as ARGX's earnings are expected to grow with 177.32% in the coming years.
PEG (NY)0.08
PEG (5Y)N/A
EPS Next 2Y310.28%
EPS Next 3Y177.32%
5. Dividend
5.1 Amount
No dividends for ARGX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
EBR:ARGX (12/8/2025, 5:36:15 PM)
783.6
+12.6 (+1.63%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners43%
Inst Owner ChangeN/A
Ins Owners0.12%
Ins Owner ChangeN/A
Market Cap48.25B
Revenue(TTM)3.60B
Net Income(TTM)1.28B
Analysts83.2
Price Target846.04 (7.97%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)15.16%
Min EPS beat(2)7.11%
Max EPS beat(2)23.2%
EPS beat(4)3
Avg EPS beat(4)3962.36%
Min EPS beat(4)-38.07%
Max EPS beat(4)15857.2%
EPS beat(8)5
Avg EPS beat(8)1996.71%
EPS beat(12)8
Avg EPS beat(12)1343.38%
EPS beat(16)12
Avg EPS beat(16)1012.62%
Revenue beat(2)1
Avg Revenue beat(2)3.68%
Min Revenue beat(2)-0.81%
Max Revenue beat(2)8.17%
Revenue beat(4)3
Avg Revenue beat(4)5.02%
Min Revenue beat(4)-0.81%
Max Revenue beat(4)8.17%
Revenue beat(8)6
Avg Revenue beat(8)5.96%
Revenue beat(12)10
Avg Revenue beat(12)14%
Revenue beat(16)13
Avg Revenue beat(16)17.53%
PT rev (1m)14.62%
PT rev (3m)16.8%
EPS NQ rev (1m)-0.95%
EPS NQ rev (3m)-0.65%
EPS NY rev (1m)7.5%
EPS NY rev (3m)21.77%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.75%
Revenue NY rev (1m)2.85%
Revenue NY rev (3m)7.66%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 73.44 | ||
| Fwd PE | 31.33 | ||
| P/S | 18.41 | ||
| P/FCF | 181.98 | ||
| P/OCF | 139.15 | ||
| P/B | 9.22 | ||
| P/tB | 9.56 | ||
| EV/EBITDA | 101.37 |
EPS(TTM)10.67
EY1.36%
EPS(NY)25.01
Fwd EY3.19%
FCF(TTM)4.31
FCFY0.55%
OCF(TTM)5.63
OCFY0.72%
SpS42.55
BVpS85.02
TBVpS81.97
PEG (NY)0.08
PEG (5Y)N/A
Graham Number142.87
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 17.84% | ||
| ROE | 21% | ||
| ROCE | 7.61% | ||
| ROIC | 5.71% | ||
| ROICexc | 15.87% | ||
| ROICexgc | 17.62% | ||
| OM | 15.3% | ||
| PM (TTM) | 41.97% | ||
| GM | 89.4% | ||
| FCFM | 10.12% |
ROA(3y)-5.23%
ROA(5y)-11.34%
ROE(3y)-5.76%
ROE(5y)-13.95%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.43
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | 0.14 | ||
| Debt/EBITDA | 0.07 | ||
| Cap/Depr | 428.74% | ||
| Cap/Sales | 3.12% | ||
| Interest Coverage | 519.07 | ||
| Cash Conversion | 82.6% | ||
| Profit Quality | 24.11% | ||
| Current Ratio | 5.6 | ||
| Quick Ratio | 5.27 | ||
| Altman-Z | 32.14 |
F-Score5
WACC7.43%
ROIC/WACC0.77
Cap/Depr(3y)176.19%
Cap/Depr(5y)545.91%
Cap/Sales(3y)10.66%
Cap/Sales(5y)13.77%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)1512.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%272.66%
EPS Next Y939.88%
EPS Next 2Y310.28%
EPS Next 3Y177.32%
EPS Next 5Y107.34%
Revenue 1Y (TTM)64.65%
Revenue growth 3Y63.92%
Revenue growth 5Y94.61%
Sales Q2Q%95.51%
Revenue Next Year94.97%
Revenue Next 2Y63.05%
Revenue Next 3Y48.34%
Revenue Next 5Y34.98%
EBIT growth 1Y207%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year1535.54%
EBIT Next 3Y218.56%
EBIT Next 5Y122.64%
FCF growth 1Y140.74%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y161.79%
OCF growth 3YN/A
OCF growth 5YN/A
ARGENX SE / ARGX.BR FAQ
What is the fundamental rating for ARGX stock?
ChartMill assigns a fundamental rating of 6 / 10 to ARGX.BR.
What is the valuation status of ARGENX SE (ARGX.BR) stock?
ChartMill assigns a valuation rating of 5 / 10 to ARGENX SE (ARGX.BR). This can be considered as Fairly Valued.
Can you provide the profitability details for ARGENX SE?
ARGENX SE (ARGX.BR) has a profitability rating of 4 / 10.
Can you provide the expected EPS growth for ARGX stock?
The Earnings per Share (EPS) of ARGENX SE (ARGX.BR) is expected to grow by 939.88% in the next year.